BioSpace News Archive

Today, Sarah Cannon announced that it will present its latest cancer research insights at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting being held virtually May 29 – 31, 2020.

Phigenics announces phiGenomics, a new Legionella testing service that harnesses the power of advanced DNA diagnostics to help prevent disease and injury associated with building water systems. phiGenomics provides defensible, accurate, and comprehensive information about the type of Legionella in a water system.

Partners with NHMA are supporting the nationwide effort to educate physicians and public health leaders on how to decrease health disparities in the U.S.

As part of the effort to help New Yorkers navigate the mental health impact of the coronavirus pandemic, the New York State Psychological Association (NYSPA) is proud to announce, in collaboration with its members, a program to provide free therapy services across the state in both English and Spanish.

CareJourney, a leading healthcare analytics company, proudly announces today its strategic partnership with Onyx Technology LLC, a NewWave company, to advance healthcare interoperability.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate in the following virtual healthcare conferences in June.

Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the initiation of INFINITY, a Phase 2, multi-center, randomized, double-masked, active comparator-controlled trial to assess a single intravitreal (IVT) injection of ADVM-022 in patients with diabetic macular edema (DME).

Digirad Corporation, a diversified holding company with three operating divisions: healthcare, building and construction, and real estate and investments, announced the closing of its previously announced underwritten public offering of 2,225,000 shares of its common stock and warrants to purchase up to 1,112,500 shares of the Company’s common stock.

Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments, today announced the closing of an oversubscribed $45 million Series C financing.